ProFibrix develops Fibrocaps, a dry powder topical tissue sealant based on fibrinogen and thrombin that rapidly stops bleeding after or during surgery. Fibrocaps is stable at room temperature, ready for immediate use, and positioned as faster and more convenient than existing liquid tissue sealants. The product is being evaluated in a prospective, multicenter Phase II study across up to 20 sites, including major U.S. and Dutch academic medical centers. If the current study confirms earlier positive Phase II results, ProFibrix expects to initiate a pivotal Phase III trial in early 2012 and to file for FDA approval in early 2013. The company will use newly secured funds to advance Fibrocaps into late-stage clinical development and to support other pipeline programs. Founded in 2004, ProFibrix is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA, and has recently made several management and Supervisory Board appointments to support commercialization and next-stage development. ProFibrix is a Leiden-based developer focused on hemostasis and regenerative-medicine products, with a lead product called Fibrocaps. Fibrocaps is a dry powder topical tissue sealant composed of fibrinogen and thrombin that rapidly stops bleeding during or after surgery. The product was in a Phase II clinical trial in the Netherlands with results expected early in 2010. ProFibrix planned to submit an IND to the U.S. FDA in the first half of 2010 and to run a combined Phase II/III pivotal study across surgical indications. The company also operates a subsidiary in Seattle, USA. Financially, ProFibrix had recently completed an €8m B round and secured additional non-dilutive financing to support clinical development. ProFibrix is a Netherlands-based developer of innovative products for hemostasis and regenerative medicine. Founded in 2004, it is headquartered in Leiden with a subsidiary in Seattle, USA. The company's pipeline includes Fibrocaps, a new tissue sealant designed to stop acute and severe bleeding during surgery or in connection with trauma injury. ProFibrix will apply the proceeds of the financing to develop Fibrocaps and other pipeline products. The company closed an $11m Series B investment. The round involved new and existing life‑science investors.

Total raised

$37M

Funding rounds

4

Latest round

Series B

Latest activity

May 2011